phase 1_2_completion
saveBayer AG — avelumab (Phase I/II Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Bone Metastasis, Malignant Neoplasms, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- phase 1 initiationasundexian: Bayer AG — asundexian (Phase I Trial Initiation)Apr 29, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- approvalNAPROXEN SODIUM: ALEVE (NAPROXEN SODIUM) — FDA approvalMar 10, 2026
comments(0)
5-min edit window · permanent after that